Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IN BRIEF: Omega Diagnostics receives CD4 deferred consideration

25th Nov 2022 11:37

Omega Diagnostics Group PLC - Alva, Scotland-based diagnostics company - Receives a deferred consideration of GBP4.0 million relating to the sale of its CD4 business.

In August, Omega sold its CD4-focused Global Health division for GBP6.1 million to Accubio Ltd, a wholly-owned subsidiary of Chinese biotechnology firm Zhejiang Orient Gene Biotech Co Ltd.

Current stock price: 4.08 pence, up 13% on Friday

12-month change: down 86%

By Abby Amoakuh; [email protected]

Copyright 2022 Alliance News Limited. All Rights Reserved.


Related Shares:

ODX.L
FTSE 100 Latest
Value8,809.74
Change53.53